Momentum Biotechnologies is a drug discovery partner that delivers innovative mass spec solutions to overcome research challenges for biopharma clients globally. Our core team of scientists and engineers started working together developing the RapidFire high-throughput MS platform and have been serving clients with MS-based services since 2004 including PureHoney Technologies (2015-23).

Momentum Biotechnologies’ goal is to accelerate our partners’ drug discovery & development programs through superior mass spec based CRO services. We help clients identify and characterize leads for degraders, molecular glues, protein-protein interaction (PPI) disrupters, RNA binders and other target classes. We use innovative techniques including affinity selection MS (ASMS), intact mass MS, chemoproteomics and small & biomolecule analyses. We pride ourselves on rapid turnaround of the highest quality data, accelerating the momentum of our clients’ research projects. We have a large Mass Spec lab with 30+ instruments and a fully functional BL2 lab in Billerica, Massachusetts.

For more information, please visit www.momentum.bio.


Biotechnology

Momentum Biotechnologies

Can Ozbal

Arrin Katz

Donald Green

William Lamarr

Daniel Brooks

The Scientific Research and Development team at Momentum Biotechnologies specializes in pioneering mass spectrometry-based solutions to support drug discovery for biopharma clients. The team, comprising experts such as Principal Scientists, Directors of Proteomics, and Research Associates, focuses on identifying and characterizing drug leads, including degraders, molecular glues, and protein-protein interaction disruptors. Utilizing advanced techniques like affinity selection MS (ASMS) and chemoproteomics, they ensure rapid, high-quality data to accelerate research projects.

Scientific Research and Development

About

Team members

Other teams at Momentum Biotechnologies

Leadership Team